; Whereas the Director of the Center for Drug Evaluation and Research of the FDA testified before Congress in 2021 that the field of neuroscience requires more research to develop new, safe, and effective treatments; Whereas the NIH and institutes within the NIH launched the Brain Research Through Advancing Innovative Neurotechnologies® (BRAIN) Initiative in 2013 and continue to partner with a number of Federal agencies and private sector partners on the BRAIN Initiative; Whereas the NIH-funded NeuroBioBank was established in September 2013 as a national resource for investigators utilizing human post mortem brain tissue and related biospecimens for their research to understand conditions of the nervous system; Whereas post mortem brain tissue is an irreplaceable resource in brain research; Whereas there is a critical need to increase the availability of human diseased and control brains and related biospecimens; Whereas one brain can provide tissue for dozens, even hundreds, of neurological studies; Whereas communities of color and poverty are underrepresented and understudied in neurological research; Whereas through awareness, the public can be educated on how brain donation for neuroscience research is not a routine part of organ donation or anatomical body donation; Whereas racial and ethnic minorities account for nearly 40 percent of the United States population and their rates of inclusion in clinical trials range from 2 to 16 percent; Whereas disparities in health status are associated with differences in socioeconomic status, whether measured by income, educational achievement, or occupation; Whereas minority and low-income communities are disproportionately impacted by neurological conditions; Whereas only 4 percent of all neurological disorder research contained in the genome-wide association studies database of the National Human Genome Research Institute includes minority participants